Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127202191 | 12720219 | 1 | I | 20160829 | 20160907 | 20160907 | EXP | US-ROCHE-1821896 | ROCHE | WON E, SHAH M, SCHODER H, STRONG V, COIT D, BRENNAN M, KELSEN D, JANJIGIAN YE, TANG L, CAPANU M, RIZK N, ALLEN P AND BAINS M. USE OF POSITRON EMISSION TOMOGRAPHY SCAN RESPONSE TO GUIDE TREATMENT CHANGE FOR LOCALLY ADVANCED GASTRIC CANCER: THE MEMORIAL SLOAN KETTERING CANCER CENTER EXPERIENCE. JOURNAL OF GASTROINTESTINAL ONCOLOGY 2016 AUG 01;7 (4):506-514. | 0.00 | Y | 0.00000 | 20160907 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127202191 | 12720219 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Unknown | DAY 1 | U | 125085 | 15 | MG/KG | SOLUTION FOR INFUSION | ||||||
| 127202191 | 12720219 | 2 | SS | CAPECITABINE. | CAPECITABINE | 1 | Oral | EVERY 21 DAYS?DAY 1 AND 8 PLUS DOCETAXEL 30 MG/M2 AND IRINOTECAN 50 MG/MG2 EVERY 21 DAYS FOR 2 CYCLE | U | 20896 | 625 | MG/M**2 | TABLET | BID | |||||
| 127202191 | 12720219 | 3 | SS | EPIRUBICIN | EPIRUBICIN | 1 | Unknown | DAY 1 | U | 0 | 50 | MG/M**2 | |||||||
| 127202191 | 12720219 | 4 | SS | CISPLATIN. | CISPLATIN | 1 | Unknown | DAY 1 | U | 0 | 60 | MG/M**2 | |||||||
| 127202191 | 12720219 | 5 | SS | DOCETAXEL. | DOCETAXEL | 1 | Unknown | DAY 1 AND 8 PLUS BEVACIZUMAB EVERY 21 DAYS FOR 2 CYCLES. | U | 0 | 30 | MG/M**2 | |||||||
| 127202191 | 12720219 | 6 | SS | IRINOTECAN | IRINOTECAN | 1 | Unknown | DAY 1 AND 8 PLUS BEVACIZUMAB EVERY 21 DAYS FOR 2 CYCLES. | U | 0 | 50 | MG/M**2 | |||||||
| 127202191 | 12720219 | 7 | SS | 5-FU | FLUOROURACIL | 1 | Intravenous (not otherwise specified) | U | 0 | 200 | MG/M**2 | SOLUTION FOR INFUSION |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127202191 | 12720219 | 1 | Adenocarcinoma gastric |
| 127202191 | 12720219 | 2 | Adenocarcinoma gastric |
| 127202191 | 12720219 | 3 | Adenocarcinoma gastric |
| 127202191 | 12720219 | 4 | Adenocarcinoma gastric |
| 127202191 | 12720219 | 5 | Adenocarcinoma gastric |
| 127202191 | 12720219 | 6 | Adenocarcinoma gastric |
| 127202191 | 12720219 | 7 | Adenocarcinoma gastric |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127202191 | 12720219 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127202191 | 12720219 | Anaemia | |
| 127202191 | 12720219 | Blood glucose abnormal | |
| 127202191 | 12720219 | Decreased appetite | |
| 127202191 | 12720219 | Dehydration | |
| 127202191 | 12720219 | Diarrhoea | |
| 127202191 | 12720219 | Electrolyte imbalance | |
| 127202191 | 12720219 | Fatigue | |
| 127202191 | 12720219 | Febrile neutropenia | |
| 127202191 | 12720219 | Gastrointestinal disorder | |
| 127202191 | 12720219 | Hypertension | |
| 127202191 | 12720219 | Leukopenia | |
| 127202191 | 12720219 | Liver function test increased | |
| 127202191 | 12720219 | Lymphopenia | |
| 127202191 | 12720219 | Mucosal inflammation | |
| 127202191 | 12720219 | Neutropenia | |
| 127202191 | 12720219 | Pain | |
| 127202191 | 12720219 | Thrombocytopenia | |
| 127202191 | 12720219 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |